Losmapimod
- Generic Name
- Losmapimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26FN3O2
- CAS Number
- 585543-15-3
- Unique Ingredient Identifier
- F2DQF16BXE
- Background
Losmapimod has been investigated for the prevention of Chronic Obstructive Pulmonary Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
- Conditions
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fulcrum Therapeutics
- Target Recruit Count
- 260
- Registration Number
- NCT05397470
- Locations
- πΊπΈ
University of California Irvine, Irvine, California, United States
πΊπΈUniversity of California Los Angeles (UCLA), Los Angeles, California, United States
πΊπΈKennedy Krieger Institute, Baltimore, Maryland, United States
Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)
- Conditions
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fulcrum Therapeutics
- Target Recruit Count
- 76
- Registration Number
- NCT04264442
- Locations
- πͺπΈ
Hospital UiP La Fe, Valencia, Spain
π«π·CHU de NICE- CHU pasteur2, Nice, France
πͺπΈHospital de la Sta Creu i St Pau, Barcelona, Spain
Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fulcrum Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT04004000
- Locations
- π³π±
Radboud University Medical Center, Nijmegen, Netherlands
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 17
- Registration Number
- NCT02000440
- Locations
- π¨π¦
GSK Investigational Site, Toronto, Ontario, Canada
A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin
- Conditions
- Interventions
- First Posted Date
- 2012-12-27
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT01756495
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.
- Conditions
- Interventions
- First Posted Date
- 2012-03-01
- Last Posted Date
- 2015-03-17
- Target Recruit Count
- 72
- Registration Number
- NCT01541852
- Locations
- π¬π§
Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom
π¬π§Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
- Conditions
- Interventions
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 604
- Registration Number
- NCT01218126
- Locations
- πΊπ¦
GSK Investigational Site, Kyiv, Ukraine
PK Study of IV Formulation of GW856553
- Conditions
- Interventions
- First Posted Date
- 2009-12-25
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT01039961
- Locations
- π¬π§
GSK Investigational Site, Cambridge, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.